About me
Dr. Jadhav brings more than eighteen years of experience in academic and industry research, pharmaceutical development and regulatory affairs experience, in US and India, with small molecules and peptides therapeutics.
He has served as the Vice President of Clinical Development and Business Strategy at CRC Pharma based in Parsippany, New Jersey. He has contributed to several drug development programs for both NCEs and 505(b)((2) across different therapeutics areas. Dr. Jadhav has represented at the US-FDA for several pre-IND, EOP1, EOP2 meetings, at the Division of Anti-infectives, Cardiovascular and Renal products, CNS, Dermatology, Pharmaceutical Quality, Oncology etc.
He is a trained clinical pharmacologist with extensive experience in planning, designing, execution, and interpretation of clinical studies (prospective, retrospective, interventional and observational) in the area of cancer, cardiovascular, and infectious diseases. He was part of the team which developed the first Indian liposomal amphotericin B (Fungisome TM), which was launched in India.
Dr. Jadhav has over thirty peer-reviewed publications, 5 issued patents, co-edited a book, and has made numerous posters and oral presentations internationally. Dr. Jadhav received his PhD in Pharmaceutics from Bombay College of Pharmacy and KEM Hospital at the University of Mumbai, India and did his Post-doctoral Fellowship at the Colleges of Pharmacy and Medicine at Univ. of Florida, Gainesville, Florida.
